number of access : ?
number of downloads : ?
ID 116106
Author
Bando, Hiroshi Tokushima University|Japan Low Carbohydrate Diet Promotion Association KAKEN Search Researchers
Keywords
Oral hypoglycemic agents (OHAs)
Sodium glucose cotransporter-2 inhibitor (SGLT-2i)
Semaglutide
Bullous pemphigoid (BP)
Hospitalization for heart failure (HHF)
Major adverse cardiovascular event (MACE)
Content Type
Journal Article
Description
Current reports for oral hypoglycemic agents (OHAs) are described. As to the association of dipeptidyl peptidase-4 inhibitors (DPP-4i) and bullous pemphigoid (BP), odds ratio (OR) was vildagliptin 5.08, linagliptin 2.87, sitagliptin 1.29 (not significant). Regarding the comparative study between SGLT2i and DPP-4i, SGLT2i group showed lower hazard ratio (HR) as MACE 0.76, myocardial infarction 0.82, cardiovascular death 0.60, heart failure 0.43, all-cause mortality 0.60. Semaglutide showed reduced OR for cardiovascular death than exenatide 0.47, dulaglutide 0.46, albiglutide 0.45, lixisenatide 0.43. SGLT2i showed reduction risk of HR for MACE 0.90, hospitalization for heart failure (HHF)/cardiovascular death 0.78, renal outcomes 0.62.
Journal Title
Diabetes Research : Open Journal
ISSN
23796375
Publisher
Openventio Publishers
Volume
7
Issue
1
Start Page
e1
End Page
e3
Published Date
2021-06-11
Rights
This is an open-access article distributed under Creative Commons Attribution 4.0 International License (CC BY 4.0)(https://creativecommons.org/licenses/by/4.0/), which allows to copy, redistribute, remix, transform, and reproduce in any medium or format, even commercially, provided the original work is properly cited.
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences